Page 1

Contacts : ● Nick Childs , IQVIA Investor Relations ( nicholas.childs@iqvia.com ) +1.973.316.3828 Tor Constantino , IQVIA Media Relations ( tor.constantino@iqvia.com ) +1.484.567.6732 IQVIA IQVIA Reports Third - Quarter 2021 Results and Raises Full - Year 2021 Guidance Revenue of $ 3,391 million for the third quarter grew 21.7 percent year - over - year GAAP Net Income of $ 261 million for the third quarter grew 158.4 percent year - over - year Adjusted EBITDA of $ 728 million for the third quarter grew 20.5 percent year - over - year GAAP Diluted Earnings per Share of $ 1.34 for the third quarter grew 157.7 percent year - over - year Adjusted Diluted Earnings per Share of $ 2.17 for the third quarter grew 33.1 percent year - over - year R & D Solutions contracted backlog of $ 24.4 billion grew 12.7 percent year - over - year Full - year 2021 guidance raised for revenue , Adjusted EBITDA , and Adjusted Diluted EPS RESEARCH TRIANGLE PARK , N.C. October 21 , 2021 – IQVIA Holdings Inc. ( " IQVIA ” ) ( NYSE : IQV ) , a leading global provider of advanced analytics , technology solutions , and clinical research services to the life sciences industry , today reported financial results for the quarter ended September 30 , 2021 . Third - Quarter 2021 Operating Results Revenue for the third quarter of $ 3,391 million increased 21.7 percent on a reported basis and 21.1 percent at constant currency compared to the third quarter of 2020. Technology & Analytics Solutions ( TAS ) revenue of $ 1,337 million grew 10.8 percent on a reported basis and 9.9 percent at constant currency . Research & Development Solutions ( R & DS ) revenue of $ 1,853 million grew 32.4 percent on a reported basis and percent at constant currency . Excluding the impact of pass throughs , R & DS revenue grew 24.7 percent year - over - year on a reported basis . Contract Sales & Medical Solutions ( CSMS ) revenue of $ 201 million grew 12.3 percent on a reported basis and 12.8 percent at constant currency . R & DS contracted backlog , including reimbursed expenses , grew 12.7 percent year - over - year to $ 24.4 billion as of September 30 , 2021. The company expects approximately $ 6.9 billion of this backlog to convert to revenue in the next twelve months . The third - quarter contracted net book - to - bill ratio was 1.39x including reimbursed expenses and 1.28x excluding reimbursed expenses . For the last twelve months ended September 30 , 2021 , the contracted net book - to - bill ratio was 1.38x including reimbursed expenses and 1.37x excluding reimbursed expenses . " We delivered another quarter of strong organic revenue growth as well as robust earnings and free cash flow , " said Ari Bousbib , chairman and CEO of IQVIA . " We exceeded our financial targets across the board , with all segments delivering strong growth . As a result of this performance , we are once again raising our full - year 2021 financial guidance . Our strong book of business across the company sets us up well to sustain our momentum into next year and beyond . " Third - quarter GAAP Net Income was $ 261 million , representing an increase of 158.4 percent compared to the third quarter of 2020 , and GAAP Diluted Earnings per Share was $ 1.34 , representing an increase of 157.7 percent compared to the third quarter of 2020. Adjusted Net Income was $ 423 million and Adjusted Diluted Earnings per Share was $ 2.17 , representing an increase of 33.1 percent compared to the third quarter of 2020. Adjusted EBITDA was $ 728 million , up 20.5 percent compared to the third quarter of 2020 . 1